The Gold Souk Extension is Ready to Welcome the World, Crowning Dubai as the Jewellery Destination of the World
27.4.2022 10:30:00 EEST | Business Wire | Press release
Ithra Dubai, a leading real estate developer and manager, fully owned by the Investment Corporation of Dubai, is pleased to announce the grand opening of the Dubai Gold Souk Extension (GSE). The opening ceremony was attended by key representatives from Ithra Dubai and Dubai Jewellery Group. An inaugural celebration with a golden line-up of entertainment, activations, and promotions will take place until May 8th, creating a festive atmosphere the whole family will enjoy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220427005005/en/
The Dubai Gold Souk Extension will rejuvenate Dubai’s historic heart of commerce and reignite Dubai’s reputation as the City of Gold, delivering an elevated shopping and trading experience. The GSE will be the crowning jewel of the Deira Enrichment Project, a modern mixed-use community developed for residential living, business, commerce, and leisure and features a transportation hub that connects Deira to the heart of Dubai, and ensures superior accessibility to the project.
The Dubai Gold Souk Extension maintains the charm and cultural characteristics of the original souk but offers a more urban experience with shaded walkways, superior facilities including workshops and co-working spaces, covered parking, restaurants, a nearby waterfront promenade, and a range of hotels; catering to residents, entrepreneurs, and tourists from around the world.
Of the 295 shops, over 50 jewellery brands have opened during the soft launch and for the grand opening, more brands and specialty restaurants are setting up shop.
Mr. Issam Galadari, Director and CEO of Ithra Dubai said, “The Gold Souk Extension is a tribute to Dubai’s legacy of trade, and we are proud to be part of it. The historic significance of this area has been uplifted to provide an enriched experience while accommodating the increasing number of visitors. Located in Dubai’s original trading hub, it will be one of Dubai’s top cultural attractions and the world’s destination for jewellery, revitalising Dubai’s moniker: the City of Gold.”
In line with Dubai’s 2040 Urban Master Plan, this 1,181,025 ft2 development will transform the Emirate’s legacy into modern reality, supporting trade, tourism, and growth to secure a golden future.
About the Deira Enrichment Project and the Gold Souk Extension:
With a mix of residential, retail, and hospitality offerings, Deira Enrichment Project will rejuvenate Dubai’s historic heart of commerce while preserving its cultural characteristics.
Deira is the cornerstone of Dubai’s trading legacy; a place rich in culture, history, and tradition. From apartments overlooking The Creek to an extension of the Deira Souk, the development will uplift the rich tapestry woven by communities past and present.
Covering a GFA area of 1,181,025 ft2, the new Gold Souk Extension will host 295+ retail units, 255,000 ft2 of office space, and 468 high-quality residences.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220427005005/en/
Contact information
Yara Bou Hadir
pressenquiries@sabaconsultants.ae
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release
PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom